FindTrial
Sign In

Phase III study of HOB-294 in patients with overactive bladder.

A phase III parallel-group comparison study of HOB-294 in patients with overactive bladder.

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221272
Enrollment
Unknown
Registered
2010-10-19
Start date
2010-10-19
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overactive bladder

Interventions

investigational material(s) Generic name etc : HOB-294 INN of investigational material : Therapeutic category code : 251 Agents affecting urinary organs Dosage and Administration for Investigational

Sponsors

Hisamitsu Pharmaceutical Co., Inc.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - Patients with symptoms of overactive bladder for at least 24 weeks before obtaining informed consent

Exclusion criteria

Exclusion criteria: - Patients with genuine stress incontinence - Patients with micturition difficulty, retention of urine, or other symptoms due to lower urinary tract obstruction - Patients for whom it is difficult to walk to the lavatory without assistance, patients who cannot measure the urine volume by themselves, and patients who cannot keep a bladder log by themselves

Design outcomes

Primary

MeasureTime frame
Efficacy—

Secondary

MeasureTime frame
Safety—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026